Provides molecular diagnostic tests that help clinicians diagnose and guide treatment for dermatologic cancers, Barrett’s esophagus, atopic dermatitis and uveal melanoma.
10-K for FY2025, filed Feb 26, 2026
Clinicians order tests, and the company bills third-party payors and patients when it delivers the test report. Payments are mainly from Medicare and commercial insurers, and timing varies with payor practices and coverage agreements.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$345.7M
10-K for FY2025, filed Feb 26, 2026
$345.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Dermatologic
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
63%
FY2022: 91%
|
Dermatologic, FY2025
$216.4M Sources
|
Sold outright |
|
Non Dermatologic
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
37%
FY2022: 8.9%
|
Non Dermatologic, FY2025
$127.9M Sources
|
Sold outright |
Treating clinicians order the tests; the company bills third-party payors, including Medicare and commercial insurers, and patients. Its sales team markets directly to clinicians and associated personnel.
10-K for FY2025, filed Feb 26, 2026Our sales and marketing efforts are primarily focused on the U.S. dermatology and gastroenterology markets. We employ our primary direct…View ↗
We bill third-party payors and patients for the tests we perform. We have received Medicare coverage for our DecisionDx-Melanoma…View ↗
Once we satisfy our performance obligations and bill for the service, the timing of the collection of payments may vary based on the…View ↗
10-K for FY2025, filed Feb 26, 2026
Our revenue for our test reports provided for patients covered by Medicare as a percentage of total revenue, was 44% and 47% for the years…View ↗
Not on paper. It lost $24.2M in FY2025, but brought in more cash than it spent: $28.3M of free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$4.1MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Jul 30, 2026
Raising full-year 2026 revenue guidance to $365-375 million from $345-355 millionConference call and webcast today at 4:30 p.m. ETView ↗
8-K, filed May 6, 2026
Raising full-year 2026 revenue guidance to $345-355 million from $340-350 millionView ↗
Growing. Revenue grew 3.7x in 4 years, from $94.1M in FY2021 to $345.7M in FY2025, about 38% a year.
Inflammatory-skin test launch
The earlier report described a pipeline test spanning psoriasis, atopic dermatitis and related conditions; the latest report describes AdvanceAD-Tx as a limited-launch test to guide systemic treatment for moderate-to-severe atopic dermatitis.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026In 2021, we announced the launch of our innovative pipeline initiative to develop a genomic test aimed at predicting response to systemic…View ↗
AdvanceAD-Tx is a non-invasive GEP test designed to guide systemic treatment selection for patients aged 12 years and older with…View ↗
IDgenetix discontinued
The earlier report listed IDgenetix as a test for mental health conditions; the latest report says Castle discontinued it.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026Dermatologic cancers—DecisionDx-Melanoma, DecisionDx®-SCC, MyPath® Melanoma and DiffDx®-Melanoma Uveal melanoma (“UM”)—DecisionDx®-UM…View ↗
Following our acquisition of AltheaDx, Inc. (“AltheaDx”) in April 2022, we began offering the IDgenetix® test, a proprietary…View ↗
DiffDx-Melanoma discontinued
The earlier report said MyPath and DiffDx-Melanoma were offered together; the latest report says Castle suspended the clinical offering of DiffDx-Melanoma.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026We further expanded our commercially available dermatologic portfolio in May 2021 when we acquired Myriad myPath, LLC (“Myriad MyPath…View ↗
(1)We began offering MyPath Melanoma following our acquisition of the Myriad MyPath Laboratory on May 28, 2021. We offered both MyPath…View ↗
Competes with SkylineDx, Interpace Diagnostics, Lucid Diagnostics, and LabCorp
10-K for FY2025, filed Feb 26, 2026Today, our principal competition for DecisionDx-Melanoma is existing traditional clinical and pathology staging criteria. While some…View ↗
Loading...